R289 在低风险骨髓增生异常综合征 (LR MDS) 患者中的研究
IRAK1/4 抑制剂 R289 的开放标签 1b 期研究,用于先前治疗难治/耐药的低危骨髓增生异常综合征 (LR MDS) 患者
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
研究概览
详细说明
An open-label, Phase 1b study of R289, an IRAK 1/4 Inhibitor, to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed/refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), luspatercept, or hypomethylating agents (HMAs) for MDS.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Strait Hicklin
- 电话号码:(650) 624-1100
- 邮箱:shicklin@rigel.com
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- 招聘中
- University of California, Los Angeles
-
Orange、California、美国、92868
- 招聘中
- University of California, Irvine
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford Cancer Institute
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- WashU Medicine
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- Oncology Clinical Research Referral Office
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Ichan School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke Cancer Institute
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Dallas、Texas、美国、75390
- 招聘中
- University of Texas, Southwestern
-
Houston、Texas、美国、77030
- 招聘中
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City、Utah、美国、84009
- 招聘中
- Intermountain Healthcare
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient must be ≥ 18 years of age at the time of signing the informed consent.
-
Must have definitive diagnosis of MDS with very low, low, or intermediate-1 risk (International Prognostic Scoring System (IPSS)-R ≤ 3.5) and ≤5% bone marrow myeloblasts.
-
Must be relapsed, refractory/resistant, intolerant, or have inadequate response to therapies with known clinical benefits for MDS, such as EPOs, luspatercept, and HMAs(i.e., azacytidine or decitabine). Patients with del (5q) must have failed prior lenalidomide therapy.
-
DOSE ESCALATION PHASE:
a. Must meet at least one of the following criteria prior to initial administration of study treatment: 1) Symptomatic anemia with hemoglobin < 9.0 g/dL and no RBC transfusion within 16 of registration or 2) RBC transfusion dependent defined as receiving ≥ 2 units of packed red blood cells (PRBCs) within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL.
-
DOSE EXPANSION PHASE:
- Relapsed, refractory to or ineligible for ESAs and has previously received one or more approved therapies for LR-MDS
- Must be RBC transfusion dependent defined as receiving ≥ 2 units of packed red blood cells (PRBCs) within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL.
-
EXPLORATORY PHASE 1b COHORT:
- Transfusion-dependent LR-MDS who are refractory or intolerant to, or are ineligible for ESAs.
- No prior therapy with any approved or investigational therapies for MDS
- No del 5q cytogenetic abnormality
- RBC transfusion dependent defined as receiving ≥ 2 units of PRBCs within 8 weeks in the preceding 16 weeks for a hemoglobin <9.0 g/dL
-
All patients must have documented marrow iron stores. If marrow iron stain is not available, the transferrin saturation must be >20% or a serum ferritin > 100ng/100mL
-
Must have Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 at screening.
-
Must have adequate organ function, defined as:
-
Hepatic function:
- aspartate amino transferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 × upper limit of normal (ULN)
- total bilirubin ≤ 1.5 × ULN
-
Renal function defined as creatinine clearance > 60 mL/min (using Cockcroft-Gault), or blood creatine < 1.5 mg/dL
-
Exclusion Criteria:
-
Prior treatment for MDS (i.e., TPOs, EPOs, luspatercept, HMAs) concluded < 4 weeks prior to study treatment
-
Clinically significant anemia resulting from iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis, or GI bleeding.
-
MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases.
-
Diagnosis of chronic myelomonocytic leukemia.
-
History of uncontrolled seizures.
-
Uncontrolled bacterial or viral infection (i.e., documented HIV, hepatitis B or hepatitis C).
-
History of other malignancy that could affect compliance or interpretation of results. Patients with an malignancy other than leukemia appropriately treated with curative intent and the malignancy has been in remission without treatment for ≥ 2 years prior to study entry are eligible as are:
- Adequately treated in situ carcinoma of the cervix uteri
- Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin, or
- Low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected.
-
History of or active, clinically significant, cardiovascular, respiratory, GI, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator's opinion (or following review by the Sponsor), could affect the conduct of the study or the absorption, metabolism or excretion of the study treatment.
-
Prior history of autologous or allogeneic stem cell transplantation
-
Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 480 milliseconds [msec]) (Common Terminology Criteria for Adverse Events [CTCAE] Grade 1) using Fridericia's QT correction formula.
-
History of additional risk factors for TdP (e.g., symptomatic heart failure with left ventricular ejection fraction [LVEF] <40%, hypokalemia, family history of Long QT Syndrome).
-
Receiving any other concurrent chemotherapy, radiotherapy, or immunotherapy (within 2 weeks of initiating study treatment), or the toxicity of the relevant prior treatment has not been resolved yet. For any long-acting systemic agent such as a monoclonal antibody, study treatment should not begin within two half-lives of the agent.
-
Use of concomitant medications that prolong the QT/QTc interval during study treatment
-
Use of concomitant medications that are strong CYP3A or CYP2B6 inhibitors or inducers during study treatment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental
ESCALATION PHASE: Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd Dose Level 4: 250 mg PO bid Dose Level 5: 500 mg PO AM/250 mg PO PM Dose Level 6: 500 mg PO bid EXPANSION PHASE (randomized 1:1): Dose Level 1: 500 mg PO qd Dose Level 2: 500 mg PO bid |
Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability
大体时间:2 Year
|
|
2 Year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Outcome Measure: Preliminary Efficacy
大体时间:24 Weeks for Primary Efficacy; 8 Weeks for Characterized PK
|
Measure Description Primary Efficacy: Proportion of patients achieving red blood cell transfusions independence by ≥ 8 weeks, ≥ 16 weeks, and ≥ 24 weeks Proportion of patients with overall response per IWG 2006 Proportion of patients with hematologic improvement per IWG 2018 Time Frame: 24 Weeks Measure Description Characterized PK Maximum plasma concentration (Cmax) Time Frame: 8 Weeks |
24 Weeks for Primary Efficacy; 8 Weeks for Characterized PK
|
|
Characterize pharmacokinetics (PK)
大体时间:8 Weeks
|
Maximum plasma concentration (Cmax) |
8 Weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Characterize pharmacodynamic (PD)
大体时间:1 year
|
Change from baseline biomarker expression levels in plasma and bone marrow (including but not limited to, C-reactive protein [CRP] and tumor necrosis factor [TNF]-a) |
1 year
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.